Abstract 1567P
Background
Long-term colorectal cancer (CRC) monitoring is common in Asia, but assessing colonoscopy effectiveness by adenoma detection rates (ADR) remains rare. The objective of this study was to evaluate the relationship between physician ADR and PCCRC incidence in sequential screening programs in order to provide up-to-date clinical evidence relevant to guiding CRC screening policies and practices.
Methods
This retrospective longitudinal observational study included participants (aged 40-74) with initial positive results and subsequent colonoscopy recruited from a community-based, multicenter, CRC screening program from January 2012 and December 2022 in Tianjin, China. ADR was defined as the proportion of colonoscopies in which at least 1 adenoma was detected. The primary outcome was PCCRC, defined as any CRC diagnosed 6 months after initial colonoscopy. ADR groups were categorized according to quartile distribution <42%, 42%-55%, 55%-64%, >64%), or dichotomized as at or above vs below the median for statistical analyses. PCCRC incidence rates were expressed as the number of events per 1000 person-years.
Results
Among 9957 included participants, 116 PCCRC cases were detected in 33881 person-years of follow-up. PCCRC incidence rates were per 1000 person-years were 4.34, 3.76, 2.62, and 2.69 from lowest to highest ADR group, respectively. ADR was significantly inversely associated with risk of PCCRC. Participants in the highest ADR group had 49% lower risk of PCCRC than low ADR group subjects (adjusted HR: 0.51, 95% CI 0.29-0.88). Multivariate-adjusted restricted cubic spline analyses identified a linear dose-response relationship between ADR and PCCRC risk.
Conclusions
Our findings show that ADR is inversely associated with risks of both PCCRC and interval PCCRC incidence, expanding the currently limited pool of data available for assessment of colonoscopy-based CRC monitoring programs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant number: 81973135), Science and Technology Commission of Shanghai Municipality (Grant number: 21XD1402600), and Tianjin Science and Technology Plan Project (Grant number: 23KPHDRC00260).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1199P - Developing and systematically validating homologous recombination repair gene detection method based on next-generation sequencing
Presenter: Yi Sun
Session: Poster session 10
1200P - Investigation of multiphoton microscopy as an innovative tool for intraoperative section-free histologic investigations in just a few minutes
Presenter: Martí Homs Soler
Session: Poster session 10
1201P - Novel deep learning model and validation of whole slide images in lung cancer diagnosis
Presenter: Alhassan Ahmed
Session: Poster session 10
Resources:
Abstract
1202P - A deep learning approach using routine pathology images to guide precision medicine in metastatic CRC
Presenter: Chaitanya Parmar
Session: Poster session 10
1203P - Analytical evaluation of whole genome sequencing for acute myeloid leukemia
Presenter: Guidantonio Malagoli Tagliazucchi
Session: Poster session 10
1204P - Real-world utility of whole genome sequencing for patients with cancer: Evaluation of a regional implementation of the 100,000 genomes project
Presenter: Helen Robbins
Session: Poster session 10
1205P - A retrospective machine learning-based analysis of nationwide cancer CGP data across cancer types to identify features associated with recommendation of mutation-based therapy
Presenter: Hiroaki Ikushima
Session: Poster session 10
1478P - Dual single-nucleotide polymorphism biomarker combination to select opioid for cancer pain management
Presenter: Yoshihiko Fujita
Session: Poster session 10
1479P - Use of rescue opioids and pain control after ketamine initiation in refractory cancer pain: A multicentric observational study
Presenter: Pablo Gallardo Melo
Session: Poster session 10
1480P - Long term therapy with denosumab and zoledronic acid: A comparative real-world retrospective observational study on skeletal-related events and pain in patients with metastatic breast cancer
Presenter: Giacomo Massa
Session: Poster session 10